249 results
8-K
EX-1.1
CYTK
Cytokinetics Inc
28 May 24
Other Events
4:01pm
of business) or long-term debt of the Company, or any material adverse changes, or any development involving a
-7-
prospective material adverse change … not have been any change in the capital stock or long term debt of the Company or any of its subsidiaries or any change or effect, or any development
424B5
CYTK
Cytokinetics Inc
24 May 24
Prospectus supplement for primary offering
4:56pm
, convertible notes, liabilities related to revenue participation right purchase agreements, and long-term debt and capitalization as of March 31, 2024 … and investments
Convertible notes, net
Liabilities related to revenue participation right purchase agreements, net
Long-term debt
Stockholders’ (deficit
424B5
CYTK
Cytokinetics Inc
22 May 24
Prospectus supplement for primary offering
4:55pm
participation right purchase agreements, and long-term debt and capitalization as of March 31, 2024:
on an actual basis;
on a pro forma basis to give effect … related to revenue participation right purchase agreements, net
Long-term debt
Stockholders’ (deficit) equity:
Preferred stock, $0.001 par value
8-K
EX-99.1
CYTK
Cytokinetics Inc
22 May 24
Other Events
4:15pm
Pharma Four Separate Components Providing $250M upon Closing; up to $575M Total Royalty Pharma R&D Partnership, Royalty Monetization, Long-term Debt … Started FOREST-HCM obstructive & non-obstructive HCM Extension study for long-term safety & efficacy Aficamten is an investigational drug
8-K
EX-99.1
CYTK
Cytokinetics Inc
13 May 24
Cytokinetics Announces Primary Results from Sequoia-hcm
4:09pm
with HCM as well as its potential long-term effects on cardiac structure and function.
Aficamten was evaluated in SEQUOIA-HCM (Safety, Efficacy
8-K
EX-99.2
rl3r0zp kwigm50
13 May 24
Cytokinetics Announces Primary Results from Sequoia-hcm
4:09pm
8-K
EX-99.1
8s8wmwgtv89elae1m
8 May 24
Cytokinetics Reports First Quarter 2024 Financial Results
4:05pm
8-K
EX-99.1
y99jerj 9p5gdb0
27 Feb 24
Cytokinetics Reports Fourth Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
l2bbe97rjhn
2 Nov 23
Cytokinetics Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
gk1znz9
19 Oct 23
Regulation FD Disclosure
7:32am
8-K
rwznox
6 Oct 23
Other Events
4:32pm
8-K
EX-99
hfqslcqfn77nfd ds1e
3 Aug 23
Cytokinetics Reports Second Quarter 2023 Financial Results
4:00pm
8-K
EX-99.1
95cijleqer
22 May 23
Other Events
6:43pm
8-K
EX-99.1
xv6j8mae83jue73
4 May 23
Cytokinetics Reports First Quarter 2023 Financial Results
4:03pm